Maripuri Saugar, Grande Joseph P, Osborn Thomas G, Fervenza Fernando C, Matteson Eric L, Donadio James V, Hogan Marie C
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Clin J Am Soc Nephrol. 2009 Sep;4(9):1423-31. doi: 10.2215/CJN.00980209. Epub 2009 Aug 13.
BACKGROUND & OBJECTIVES: Renal pathology and clinical outcomes in patients with primary Sjögren's syndrome (pSS) who underwent kidney biopsy (KB) because of renal impairment are reported.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Twenty-four of 7276 patients with pSS underwent KB over 40 years. Patient cases were reviewed by a renal pathologist, nephrologist, and rheumatologist. Presentation, laboratory findings, renal pathology, initial treatment, and therapeutic response were noted.
Seventeen patients (17 of 24; 71%) had acute or chronic tubulointerstitial nephritis (TIN) as the primary lesion, with chronic TIN (11 of 17; 65%) the most common presentation. Two had cryoglobulinemic GN. Two had focal segmental glomerulosclerosis. Twenty patients (83%) were initially treated with corticosteroids. In addition, three received rituximab during follow-up. Sixteen were followed after biopsy for more than 12 mo (median 76 mo; range 17 to 192), and 14 of 16 maintained or improved renal function through follow-up. Of the seven patients presenting in stage IV chronic kidney disease, none progressed to stage V with treatment.
This case series supports chronic TIN as the predominant KB finding in patients with renal involvement from pSS and illustrates diverse glomerular lesions. KB should be considered in the clinical evaluation of kidney dysfunction in pSS. Treatment with glucocorticoids or other immunosuppressive agents appears to slow progression of renal disease. Screening for renal involvement in pSS should include urinalysis, serum creatinine, and KB where indicated. KB with characteristic findings (TIN) should be considered as an additional supportive criterion to the classification criteria for pSS because it may affect management and renal outcome.
报告因肾功能损害接受肾活检(KB)的原发性干燥综合征(pSS)患者的肾脏病理及临床结局。
设计、地点、参与者及测量指标:7276例pSS患者中有24例在40年期间接受了KB。肾病理学家、肾病学家和风湿病学家对患者病例进行了回顾。记录了临床表现、实验室检查结果、肾脏病理、初始治疗及治疗反应。
17例患者(24例中的17例;71%)以急性或慢性肾小管间质性肾炎(TIN)为主要病变,其中慢性TIN最为常见(17例中的11例;65%)。2例有冷球蛋白血症性肾小球肾炎。2例有局灶节段性肾小球硬化。20例患者(83%)初始接受糖皮质激素治疗。此外,3例在随访期间接受了利妥昔单抗治疗。1十六条患者在活检后随访超过12个月(中位时间76个月;范围17至192个月),16例中的14例在随访期间肾功能维持或改善。7例IV期慢性肾脏病患者经治疗后均未进展至V期。
该病例系列支持慢性TIN是pSS肾脏受累患者KB的主要发现,并显示了多种肾小球病变。在pSS患者肾功能障碍的临床评估中应考虑进行KB。糖皮质激素或其他免疫抑制剂治疗似乎可减缓肾脏疾病进展。pSS肾脏受累的筛查应包括尿常规、血清肌酐,并在必要时进行KB。具有特征性表现(TIN)的KB应被视为pSS分类标准的一项额外支持标准,因为它可能影响治疗及肾脏结局。 (注:原文中“十六条”表述有误,应为“16例”)